Zanidatamab Regimens Exceed China Cost Thresholds for Advanced Gastroesophageal Adenocarcinoma
A partitioned survival model indicates that first-line zanidatamab regimens for HER2-positive advanced gastroesophageal adenocarcinoma exceed China's willingness-to-pay threshold despite improving ...

